Documentos de Académico
Documentos de Profesional
Documentos de Cultura
0
0 6 12 18 24 30 36
Time from randomization
Number at risk
Pioglitazone 2488 2373 2302 2218 2146 348
Placebo 2530 2413 2317 2215 2122 345
*Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.
PROactive: Reduction in secondary outcome
All-cause mortality, MI (excluding silent MI), stroke
25
20
Placebo
16% Relative
15 risk reduction
(358 events)
Proportion HR* 0.84 (0.72–0.98)
of events 10 P = 0.027
(%) Pioglitazone
(301 events)
5
0
0 6 12 18 24 30 36
Time from randomization
Number at risk
Pioglitazone 2536 2487 2435 2381 2336 396
Placebo 2566 2504 2442 2371 2315 390
*Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.
PROactive: Summary
Pioglitazone added to standard antidiabetic and CV therapies showed:
• 10% RRR in primary outcome
– Composite all-cause mortality, nonfatal MI (including silent MI),
stroke, ACS, leg amputation, coronary or leg revascularization
• 16% RRR in secondary outcome
– All-cause mortality, nonfatal MI (excluding silent MI) or stroke
• No difference between groups in HF mortality
• Continued divergence in survival curves
– Greater benefit with longer treatment duration hypothesized
Saxa ICC
TECOS3 Sitagliptin vs placebo T2DM with pre-existing Completado
CVD
I DPP 4 I SGLT 2
Disminuye Aumenta Glucagón
Glucagón
Estudios con GLP 1 y MACE
Nombre del Producto Población Dosis N Resultado
Estudio